Premium
Antidiabetic medication use in commercially insured children and adolescents in the United States from 2004 to 2019
Author(s) -
Sun Jenny W.,
HernándezDíaz Sonia,
Bourgeois Florence T.,
Haneuse Sebastien,
Brill Gregory,
Bateman Brian T.,
Huybrechts Krista F.
Publication year - 2021
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.14237
Subject(s) - medicine , metformin , medical prescription , insulin , liraglutide , diabetes mellitus , cohort , population , pediatrics , type 2 diabetes , pharmacology , endocrinology , environmental health
Aim To describe the patterns of non‐insulin antidiabetic medication use, initiation and adherence in the paediatric population. Methods We conducted a descriptive study of non‐insulin antidiabetic medication use in children and adolescents (aged 10‐18 years) using real‐world data from a nationwide US commercial claims database (January 2004–September 2019). Trends in the prevalence of non‐insulin antidiabetic medication use overall and by class were evaluated. Among new users of non‐insulin antidiabetic agents, medication adherence was examined using group‐based trajectory models. Results In a cohort of more than 1 million paediatric patients, the prevalence of any non‐insulin antidiabetic medication use was 75.7 per 100 000 patients in 2004 and more than doubled to 162.0 per 100 000 in 2019. Biguanides (metformin) was by far the most widely used medication class. The use of newer classes was low (<10 per 100 000), but there was an uptake in the use of glucagon‐like peptide‐1 receptor agonists after liraglutide received paediatric approval in 2019. Medication adherence was poor during the 18 months after treatment initiation: 79.6% of initiators experienced an early treatment interruption (median time to interruption: 90 days among metformin monotherapy initiators) and 21% of initiators did not return for a prescription refill after the first month. Conclusions There was a substantial increase in non‐insulin antidiabetic medication use among commercially insured paediatric patients from 2004 to 2019. Nearly all patients were treated with metformin, while the use of newer agents remained low. Despite the increase in medication use, short treatment episodes were observed, even among patients with a diagnosis of type 2 diabetes, raising concern over poor adherence.